12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Deals

arGEN-X B.V., Shire deal

The companies added an additional antibody program to a March 2012 deal under which arGEN-X is using its SIMPLE Antibody platform to isolate and characterize antibodies against targets selected by...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >